Innate Pharma S.A.

EPA:IPH.PA

2.05 (EUR) • At close September 18, 2024
Bedrijfsnaam Innate Pharma S.A.
Symbool IPH.PA
Munteenheid EUR
Prijs 2.05
Beurswaarde 165,945,091
Dividendpercentage 0%
52-weken bereik 1.862 - 2.8
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mondher Mahjoubi M.D.
Website https://www.innate-pharma.com

An error occurred while fetching data.

Over Innate Pharma S.A.

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well

Vergelijkbare Aandelen

Carmat SA logo

Carmat SA

ALCAR.PA

1.75 EUR

Transgene SA logo

Transgene SA

TNG.PA

1.038 EUR

Eurobio Scientific Société anonyme logo

Eurobio Scientific Société anonyme

ALERS.PA

24.9 EUR

Laboratorio Reig Jofre, S.A. logo

Laboratorio Reig Jofre, S.A.

RJF.MC

2.7 EUR

Biosynex SA logo

Biosynex SA

ALBIO.PA

4.335 EUR

Prim, S.A. logo

Prim, S.A.

PRM.MC

10.65 EUR

Malin Corporation plc logo

Malin Corporation plc

MLC.IR

6.1 EUR

Median Technologies SA logo

Median Technologies SA

ALMDT.PA

4.07 EUR

Bastide Le Confort Médical SA logo

Bastide Le Confort Médical SA

BLC.PA

20.15 EUR

Nanobiotix S.A. logo

Nanobiotix S.A.

NANO.PA

4.454 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)